Épisodes

  • Biohacking in 2026: AI Coaching, Peptides, and the Regulatory Gray Zone

    Biohacking in 2026: AI Coaching, Peptides, and the Regulatory Gray Zone
    Mar 25 2026
    In the past 48 hours as of late March 2026, the biohacking industry shows steady momentum amid growing mainstream adoption, though specific market disruptions remain limited. Longevity clinics and peptide suppliers are booming, with BPC-157 and TB-500 peptides drawing intense focus for joint health, muscle gain, and sleep optimization, despite lacking high-quality human trials and operating in a regulatory gray zone bypassing FDA potency testing.[2]

    No major deals, partnerships, or product launches surfaced in this window, but consumer behavior shifts toward hyper-personalization are accelerating, including home biomarker tests, continuous glucose monitors, and AI health coaching. A Stanford study notes AI coaching boosts daily steps, nutrition, and sleep, with human-AI pairings doubling results.[2] Altitude training via hypoxic devices is emerging as a breakthrough for endurance and recovery by boosting red blood cell production.[2]

    Regulatory pressures persist, highlighted by a 2025 Clinica Family Health data breach affecting wellness-linked services, underscoring biosecurity risks in biohacking data flows.[3] An upcoming Berkeley panel on March 30 explores biohacking's legal and food system implications, signaling rising scrutiny.[5][6]

    Leaders like Upgrade Labs continue pushing biohacking for strength and recovery, but face Wild West dynamics from unverified influencers.[2][3] Compared to prior reports, China's dominance in CAR-T trials and bio-data acquisition threatens U.S. supply chains, as noted in ongoing biosecurity discussions, with no new counters in the last week.[1]

    No verified statistics from the past week emerged on market movements or price changes, though fiber intake trends (25-35g daily) reflect basics overtaking experimental hacks.[2] Supply chains show vulnerability, with outsourced pharma from China eroding U.S. edges in gene editing like CRISPR.[1] Overall, biohacking tilts mainstream yet experimental, prioritizing personalization over fundamentals. (278 words)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI
    Voir plus Voir moins
    3 min
  • From Fringe to Mainstream: The Biohacking Boom Reshaping Retail and Longevity Markets in 2024

    From Fringe to Mainstream: The Biohacking Boom Reshaping Retail and Longevity Markets in 2024
    Mar 24 2026
    Biohacking Industry Current State Analysis: Past 48 Hours Snapshot

    In the past 48 hours, the biohacking sector shows robust mainstreaming, with retailers aggressively integrating longevity-focused products amid explosive market growth. The global biohacking market, valued at 24.5 billion dollars in 2024, is projected to surge over fourfold to 111.3 billion dollars by 2034, driven by demand for supplements, wearables, and cellular health innovations.[1]

    No major deals, partnerships, or regulatory changes surfaced in the latest reports, but consumer behavior shifts are pronounced. NielsenIQ data reveals beauty evolving into a holistic lifestyle category, expanding industry value by over 60 percent in 2026; 50 percent of global consumers prioritize self-care more than five years ago, 44 percent plan increased vitamin and supplement use, and 63 percent rate sleep higher, boosting ingestibles and devices.[1] The supplements market, a 40 billion dollar opportunity, grows at 9.5 percent CAGR to 60 billion by 2035, signaling biohacking's optimization mindset.[2]

    Emerging trends include nutricosmetics overlapping with longevity, featuring personalized supplements via AI and NAD-plus peptides for metabolic beauty; collagen dominates, with proactive anti-aging framing skin as biological vitality.[4][1] Platforms like iHerb aggregate 20,000-plus SKUs for mass access, while physical stores like Mecca's 220-square-meter Apothecary curate sleep, gut, and ritual products.[1]

    Leaders respond with science-backed trust: Therabody forms Scientific Advisory Boards with institutions like the American College of Sports Medicine; Bon Charge uses independent testing for blue-light blockers; Ammortal appoints a chief medical officer for premium recovery chambers.[1] GLP-1 drugs, with 83 percent awareness, cut grocery spending 4 percent and fast food 5 percent, indirectly pressuring biohacking via intentional eating, though no direct disruptions noted.[2]

    Compared to prior reports, growth accelerates from wellness tourism's 651 billion dollars in 2024 (16.6 percent annual rise), shifting from fringe to retail ecosystems without price hikes or supply issues in recent data. Retailers curating evidence-based rituals position biohacking as a trust-driven longevity gold rush.[1]

    (Word count: 298)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI
    Voir plus Voir moins
    3 min
  • Biohacking Goes Mainstream: 111 Billion Dollar Market Boom and FDA Peptide Approval Signal

    Biohacking Goes Mainstream: 111 Billion Dollar Market Boom and FDA Peptide Approval Signal
    Mar 23 2026
    Current State Analysis of the Biohacking Industry: Past 48 Hours

    In the last 48 hours as of March 23, 2026, the biohacking industry shows accelerating mainstream adoption, with retailers aggressively integrating biohacking products amid surging consumer demand for longevity-focused wellness.[1] The global market, valued at 24.5 billion USD in 2024, is projected to exceed 111 billion USD by 2034, driven by a shift from anti-aging to cellular health optimization via NAD+ and peptides.[1]

    Key developments include Mecca's Apothecary expansion in Melbourne, a 220-square-meter wellness hub curating biohacking rituals around sleep, gut health, and calm, blending supplements, devices, and adaptogens into retail experiences.[1] In Asia, demand for US-manufactured cognitive enhancers like Momentous Magnesium Threonate spikes in Malaysia, Singapore, and Hong Kong, with regional markups highlighting supply chain premiums for high-purity brain optimization products.[2][7]

    Regulatory momentum builds as RFK Jr. signals FDA action on peptides—mini-proteins biohackers use for metabolic and hormonal tweaks—potentially widening access after a promised review, contrasting prior restrictions that sparked lawsuits from compounding pharmacies.[8] This could supercharge the 100 billion USD peptide market projected this decade.[8]

    Leaders respond to trust gaps with science: Therabody partners with the American College of Sports Medicine for validated red light devices; Bon Charge touts independent testing for blue light blockers; Ammortal appoints a longevity chief medical officer for premium recovery chambers.[1] NielsenIQ data from the past week reveals 50 percent of consumers prioritize self-care more than five years ago, 44 percent plan supplement increases, and 63 percent elevate sleep, fueling 60 percent growth in holistic beauty.[1]

    Compared to prior reports, hydrogen water trends noted in early 2026 forecasts remain nascent without fresh launches, while retail mainstreaming outpaces them.[5] No major deals, disruptions, or price drops surfaced, but educated shoppers demand evidence, positioning transparent brands for dominance in this trust-driven surge.[1][8]

    (Word count: 298)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI
    Voir plus Voir moins
    2 min
  • Biohacking Market Boom: 18.75% Growth Through 2032, But Skepticism Rises

    Biohacking Market Boom: 18.75% Growth Through 2032, But Skepticism Rises
    Mar 20 2026
    The biohacking industry shows steady growth momentum over the past 48 hours, with no major disruptions but continued hype around cognitive and energy supplements. The global biohacking market was valued at USD 29,526.01 million in 2025 and is projected to reach USD 98,319.59 million by 2032, expanding at a compound annual growth rate of 18.75 percent.[1] This forecast, updated March 16, underscores robust long-term demand, though no fresh statistics from the last week alter this trajectory.

    Recent buzz centers on emerging products like a supplement formulation promoted by Ghassan Salame, marketed as a 2026 breakthrough for cognitive support and energy in biohacker circles.[2] No verified deals, partnerships, or new launches were confirmed in the past 48 hours, and regulatory changes remain absent from reports.

    Criticism highlights risks, with Salt Lake City exemplifying issues in the space: charismatic founders pushing compelling but unproven narratives.[3] This reflects ongoing consumer behavior shifts toward skepticism amid hype, contrasting quieter periods without such spotlight.

    No price changes, supply chain issues, or emerging competitors surfaced recently. Leaders like those behind these supplements respond by doubling down on marketing claims, prioritizing narrative over rigorous validation. Compared to prior reporting, current conditions mirror stable 2025 estimates without acceleration or downturns, signaling a maturing yet controversy-prone sector focused on wearables and nootropics. (248 words)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI
    Voir plus Voir moins
    2 min
  • Peptide Boom: FDA Loosening Rules, Market Hits $52.6B, What You Need to Know

    Peptide Boom: FDA Loosening Rules, Market Hits $52.6B, What You Need to Know
    Mar 19 2026
    In the past 48 hours, the biohacking industry shows momentum from regulatory shifts and product innovations, with RFK Jr. pushing to loosen FDA restrictions on nearly 20 peptides like ipamorelin, CJC-1295, BPC-157, and TB-500, potentially enabling U.S. compounding pharmacies to supply higher-quality versions and curb risky online imports.[1] This follows his recent Joe Rogan podcast comments, drawing support from physicians like Dr. Sue Decotiis for safer access under medical guidance, though experts caution on unproven safety and lack of human trials for many compounds.[1]

    Market data highlights growth: the global longevity ingredients sector, overlapping biohacking, hit $984.27 million in 2025 and projects $1,706.40 million by 2033 at 7.12% CAGR, with peptides and amino acids claiming 15% share; North America leads at 35%.[2] March 2026 saw spermidine supplements named U.S. award finalists for autophagy support and NAD+ injectable pens launch at wellness centers, signaling consumer shifts toward cellular repair tools.[2] Peptides overall reached a $52.6 billion market, with GLP-1 adoption at 1 in 8 U.S. adults.[8]

    New launches include U: The Mind Company's non-invasive brain device, an amplitude-modulated alternative to Neuralink, targeting focus and memory for biohackers; its Parkinson's trial is underway.[5] Weight-loss patches mimicking GLP-1 effects like Ozempic emerged as a 2026 trend, avoiding injections.[6]

    No major deals, disruptions, or price shifts reported in the last week, but leaders like Finnrick Analytics address supply impurities via testing.[1] Compared to early 2026's NAD+ gut health studies, current buzz amplifies peptides amid policy thaw, boosting influencer-driven demand without evident consumer pullback. Industry responds by prioritizing ethical sourcing and trials for credibility.[1][2] (298 words)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI
    Voir plus Voir moins
    2 min
  • Biohacking Conferences 2026: From Optimization Fatigue to Invisible Health Tech

    Biohacking Conferences 2026: From Optimization Fatigue to Invisible Health Tech
    Mar 18 2026
    The biohacking industry shows steady momentum in the past 48 hours, driven by major conference announcements rather than market disruptions or new deals. On March 17, 2026, Biohackers World revealed plans for its March 28-29 Los Angeles event, expecting over 1,500 attendees, 35 speakers, and 75 exhibitors focused on longevity science, AI health data, microbiome research, and testable wellness tech like light therapies.[1] Similarly, Dave Asprey announced the speaker lineup for his 14th annual BEYOND Biohacking Conference on May 27-29 in Austin, featuring experts like Jay Shetty, Dr. Gabrielle Lyon, and Patrick Kennedy, with 150 exhibitors offering PEMF therapy, stem cells, and hyperbaric oxygen.[2][3]

    No verified market movements, price changes, partnerships, regulatory shifts, or supply chain issues emerged in the last week; data remains sparse. The global wellness economy, tied to biohacking, hit 5.6 trillion dollars in 2023 and is projected to reach 8.5 trillion by 2027, reflecting sustained growth in wearables and metabolic tracking.[1]

    Consumer behavior hints at a backlash against over-optimization, with fatigue from constant self-surveillance pushing toward "invisible care" tech that embeds health monitoring without screens, per 2026 wellness trends.[5] New product launches include Reaper's Remedies "Die Slower" vitamins on March 17, satirizing longevity hype in a crowded field.[7]

    Leaders like Asprey respond by expanding beyond protocols to consciousness and nervous system regulation, emphasizing meaningful life over mere lifespan extension.[2][3] Mick Safron of Biohackers World highlights a shift from quick fixes to structured, data-driven everyday health.[1] Compared to prior reporting, this builds on rising preventive health interest without major pivots, positioning Austin and LA as hubs amid no evident disruptions. Overall, the sector buzzes with events amid subtle consumer pushback on hyper-tracking.(298 words)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI
    Voir plus Voir moins
    2 min
  • AI Biohacking Revolution: How Digital Biology and Luxury Wellness are Reshaping Health in 2026

    AI Biohacking Revolution: How Digital Biology and Luxury Wellness are Reshaping Health in 2026
    Mar 17 2026
    In the past 48 hours, the biohacking industry shows strong momentum driven by AI integration and luxury wellness demand. Nvidia CEO Jensen Huang highlighted digital biology as the next revolution, emphasizing AI for programmable biology and faster drug discovery, potentially slashing traditional 10 to 15 year timelines and 2 billion dollar costs.[1] This vision spotlights companies like Totaligent, which announced two binding Letters of Intent in February 2026 but gained fresh attention yesterday via market reports; one expands AI biologics via Aetherium acqui-hire, the other forms a joint venture with Japans GloMed Solutions, adding 10 million dollars annual revenue and 1 million in free cash flow from APAC clinics focused on peptides for metabolic and anti-aging therapies popular in biohacking.[1][2]

    New product buzz centers on the Ammortal Chamber, a 160,000 dollar home biohacking pod using red light, PEMF, and molecular hydrogen for inflammation reduction, ATP boost, and recovery; sessions start at 125 dollars, with elite athletes tracking gains via Oura Rings.[3] Upgrade Labs, an AI-driven fitness biohacking franchise, plans its Boulder, Colorado debut on March 27, expanding from California amid wellness booms.[4]

    Consumer shifts are evident: 60 percent of luxury buyers plan higher 2026 wellness spending in the 6.3 trillion dollar industry, fueling peptide injectables and cognitive programs like The Brain Song, reviewed March 15 for focus enhancement.[3][6] No major regulatory changes or disruptions reported, but supply chains strengthen via partnerships like Totaligents APAC push.

    Compared to prior weeks quieter news, this surge ties to Huangs comments, with leaders like Recursion Pharmaceuticals and Tempus AI leveraging Nvidia GPUs for data-heavy biohacks, reducing discovery from 42 to 18 months.[1] Biohacking evolves from niche to mainstream, blending AI precision with indulgent tech for longevity seekers. (298 words)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI
    Voir plus Voir moins
    2 min
  • Biohacking Wellness Tourism: Thailand's $4.5 Trillion Ecosystem Revolution in 2026

    Biohacking Wellness Tourism: Thailand's $4.5 Trillion Ecosystem Revolution in 2026
    Mar 16 2026
    In the past 48 hours, the biohacking industry shows strong momentum in wellness tourism and performance optimization, with Thailand emerging as a key hub. On March 16, 2026, BDMS Wellness Clinic announced a major public-private alliance, partnering with biotech giants like Illumina and Abbott, the Tourism Authority of Thailand, and luxury providers to build a science-driven wellness ecosystem. This includes biohacking treatments, personalized diagnostics, and preventive care integrated with high-end travel, targeting Asias fast-growing wellness tourism sector amid a global 4.5 trillion wellness economy.[1]

    Consumer behavior shifts toward biohacking for work performance, as wearables like Whoop and Apple Watch track heart rate variability (HRV) to boost productivity. Tech workers in San Francisco compare HRV scores socially, while professionals in law and finance adopt infrared saunas, red light therapy, and continuous glucose monitors. Some limit rituals after observing over-optimization leading to burnout, reflecting AI-driven job anxieties.[3]

    New product integrations appear in luxury spas: The Longevity SPA at Lake Como EDITION launched biohacking therapies like Dry Float, Near Infra-Red, and Hydrogen Oxygen treatments for cellular regeneration, blending tech with holistic rituals.[6] No major deals, regulatory changes, or disruptions reported in the last week, but Thailand's initiative contrasts prior reporting by expanding biohacking beyond gadgets into tourism ecosystems, unlike isolated wearable trends.

    Leaders like BDMS respond to health tourism demand by orchestrating global partnerships, while execs like Dr. Ravi Solanki foster team biohacking culture for unity and performance. No verified stats from the past week beyond wellness economys scale, but growth signals sustained interest without price or supply chain shifts. This positions biohacking for broader accessibility in 2026.[1][3][6]

    (Word count: 298)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI
    Voir plus Voir moins
    2 min